EFFICACY AND SAFETY OF ADDING SITAGLIPTIN TO BASAL INSULIN THERAPY

Abstract

ABSTRACT Background: Some of the options where blood glucose regulation cannot be achieved with basal insulin - oral antidiabetic pheasant is the addition of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, to the treatment. This is what writes on glycemic control and body writing and prompting for the addition of sitagliptin to basal insulin therapy with metformin and / or other oral antidiabetics. Methods: The study included 52 patients who had been on sitagliptin and sitagliptin for at least 3 months on basal insulin therapy with metformin and / or other oral antidiabetic agents. Anthopometric and clinical features such as age, gender, BMI and FBG, HbA1c and other metabolic parameters were examined. Results: The average age of 43 patients, 29 (67.5%) female and 14 (32.5%) males, was 54.3 and their body mass index was 34.8 kg / m2 at the beginning of the treatment. It was determined that the mean HbA1c levels, which were 9.1 ± 1.5% at the beginning, decreased to 8.2 ± 1.7% by decreasing 0.89% in the 3rd month after sitagliptin was added to the treatment (p <0.05). It was observed that the fasting blood glucose, which was 203.9 ± 76.2 at the beginning, decreased by 34.2 ± 74.9 mg / dl in the 3rd month with the addition of sitagliptin to the treatment (p <0.05). There was no significant change in patients' body weight; no serious adverse effects or severe hypoglycemia attack was detected. Conclusion: The addition of sitagliptin to the treatment where adequate glycemic control cannot be achieved with metformin and / or other oral antidiabetic and basal insulin is an effective and good option.

Background: Some of the options where blood glucose regulation cannot be achieved with basal insulin - oral antidiabetic pheasant is the addition of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, to the treatment. This is what writes on glycemic control and body writing and prompting for the addition of sitagliptin to basal insulin therapy with metformin and / or other oral antidiabetics. Methods: The study included 52 patients who had been on sitagliptin and sitagliptin for at least 3 months on basal insulin therapy with metformin and / or other oral antidiabetic agents. Anthopometric and clinical features such as age, gender, BMI and FBG, HbA1c and other metabolic parameters were examined. Results: The average age of 43 patients, 29 (67.5%) female and 14 (32.5%) males, was 54.3 and their body mass index was 34.8 kg / m2 at the beginning of the treatment. It was determined that the mean HbA1c levels, which were 9.1 ± 1.5% at the beginning, decreased to 8.2 ± 1.7% by decreasing 0.89% in the 3rd month after sitagliptin was added to the treatment (p <0.05). It was observed that the fasting blood glucose, which was 203.9 ± 76.2 at the beginning, decreased by 34.2 ± 74.9 mg / dl in the 3rd month with the addition of sitagliptin to the treatment (p <0.05). There was no significant change in patients' body weight; no serious adverse effects or severe hypoglycemia attack was detected. Conclusion: The addition of sitagliptin to the treatment where adequate glycemic control cannot be achieved with metformin and / or other oral antidiabetic and basal insulin is an effective and good option.